BIOFRONTERA INC(NASDAQ:BFRI) stock News

BFRI Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: BEAT APDN ONMD SAGE ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

a month ago - By: Biofrontera Inc.

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

2 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

2 months ago - By: Benzinga - Mentions: DOCS AMAT SATL PTIX ...

Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

2 months ago - By: Biofrontera Inc.

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

2 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

3 months ago - By: Zacks Investment Research - Mentions: KYMR

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: NTLA

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: ACCESS Newswire

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

a year ago - By: BusinessInsider

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

3 months ago - By: Biofrontera Inc.

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

4 months ago - By: Biofrontera Inc.

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

4 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

5 months ago - By: Biofrontera Inc.

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

7 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

7 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

8 months ago - By: Biofrontera Inc.

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

8 months ago - By: Biofrontera Inc.

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

9 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

9 months ago - By: Biofrontera Inc.

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

10 months ago - By: Biofrontera Inc.

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

a year ago - By: InvestorPlace

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

a year ago - By: Biofrontera Inc.

BIOFRONTERA INC (BFRI) Stock News

BFRI Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Monday's Pre-Market Session

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update